HEALTHCARE RESOURCE USE AND COSTS OF CARE IN HR+/HER2-METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY

被引：0
|
作者：
Collin, S. [1 ]
Tse, J. [2 ]
Shaikh, N. F. [3 ]
Near, A. [2 ]
Hamilton, E. [4 ]
Brufsky, A. [5 ]
Gradishar, W. [6 ]
Mehta, S. [7 ]
Long, G. H. [1 ]
Toms, N. [1 ]
机构：
[1] AstraZeneca Pharmaceut Ltd, Cambridge, England
[2] IQVIA, Durham, NC USA
[3] IQVIA, Morgantown, WV USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[7] Daiichi Sankyo, Basking Ridge, NJ USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE417
引用
下载
收藏
页码：S134 / S134
页数：1
相关论文
共 50 条
  • [1] VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA
    Chin, A.
    Ip, Q.
    Wu, X.
    Lyle, D.
    VALUE IN HEALTH, 2024, 27 (06) : S163 - S163
  • [2] Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2-metastatic breast cancer: A retrospective claims study in the US
    Li, N.
    Hao, Y.
    Kageleiry, A.
    Peeples, M.
    Fang, A.
    Koo, V.
    Guerin, A.
    CANCER RESEARCH, 2016, 76
  • [3] Comparison of healthcare resource utilization and costs in women with HR+/HER2-metastatic breast cancer treated with ribociclib vs palbociclib or abemaciclib
    Balu, Sanjeev
    Burne, Rebecca
    Guerin, Annie
    Bungay, Rebecca
    Paul, Mary Lisha
    Sin, Roxana
    CANCER RESEARCH, 2021, 81 (04)
  • [4] Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2-metastatic breast cancer: a retrospective US claims study
    Guerin, Annie
    Hao, Yanni
    Tang, Derek
    Peeples, Miranda
    Fang, Anna
    Kageleiry, Andrew
    Koo, Valerie
    Li, Nanxin
    Wu, Eric Q.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (09) : 1189 - 1196
  • [5] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [6] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [7] Real-world treatment patterns, healthcare resource utilization and costs of care among newly-diagnosed patients with HR+/HER2-metastatic breast cancer
    Basho, Reva K.
    Ng, Carmen
    Dillon, Allison
    Chen, Lu
    Cheng, Anna
    Du Toit, Yolande
    Abbass, Ibrahim M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Treatment patterns and resource utilization among patients with HR+/HER2-metastatic breast cancer in a privately insured US population
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    CANCER RESEARCH, 2017, 77
  • [9] Experience with eribulin in HR+/HER2-metastatic breast cancer, including a male
    Munoz Sanchez, Maria del Mar
    Soriano Rodriguez, Maria del Carmen
    Molina Garrido, Maria Jose
    Lopez-Gonzalez, Ana
    Garcia-Palomo, Andres
    Lopez-Gonzalez, Laura
    Plata Fernandez, Maria Yessica
    Luque Caro, Natalia
    Sanchez Rovira, Pedro
    FUTURE ONCOLOGY, 2018, 14 (07) : 5 - 12
  • [10] Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?
    Loibl, Sibylle
    Holtschmidt, Johannes
    LANCET, 2023, 402 (10411): : 1394 - 1395
12345